Dangerous Drug: Vinorelbine Tartrate(vin oh rel’ been)
Navelbine
PREGNANCY CATEGORY D
Drug Classes
Antineoplastic
Mitotic inhibitor
Therapeutic Actions
Inhibits microtubule formation in the mitotic spindle, leading to cell-cycle arrest in dividing cells in metaphase.
Indications
First-line treatment of ambulatory patients with unresectable advanced non–small-cell lung cancer
Treatment of stage IV non–small-cell lung cancer alone or with cisplatin
Treatment of stage III non–small-cell lung cancer with cisplatin
Unlabeled uses: Breast cancer, ovarian cancer, Hodgkin lymphoma, desmoid tumors and fibromatosis, advanced Kaposi sarcoma, non-Hodgkin lymphoma
Contraindications and Cautions
Contraindicated with allergy to vinca alkaloids, pretreatment granulocyte counts of 1,000 cells/mm3 or less, pregnancy, lactation.
Use cautiously with liver disease.
Available Forms
Injection—10 mg/mL
Dosages
Adults
Warning Do not administer more than once a wk because of leukopenic response.
Monotherapy: Initial dose, 30 mg/m2 as single IV dose; repeat once a wk until progression of disease or toxicity limits use.
With cisplatin: 25 mg/m2 IV every 7 days in combination with cisplatin 100 mg/m2 IV given every 4 wk, or 30 mg/m2 IV with cisplatin 120 mg/m2 IV given on days 1 and 29, then every 6 wk.
Pediatric patients
Safety and efficacy not established.
Patients with hepatic impairment
If total serum bilirubin concentration is 2.1–3 mg/dL, reduce dose to 50% of starting dose; if greater than 3 mg/dL, reduce to 25% of starting dose.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
